Contineum Therapeutics approves 2026 Inducement Plan with 750,000 share reserve

Contineum Therapeutics, Inc.

Board approved 2026 Employment Inducement Equity Incentive Plan on January 23, 2026.
Plan reserves 750,000 shares of Class A common stock for awards to new employees as inducement material.
Adopted without stockholder approval under Nasdaq Rule 5635(c)(4); no incentive stock options allowed.
Substantially similar to existing 2024 Equity Incentive Plan except for ISO prohibition and eligible recipients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.